Does long-term use of ticagrelor reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with a myocardial infarction more than 1 year previously?
Patients with a myocardial infarction more than 1 year previously
Ticagrelor (long-term use)
Composite of cardiovascular death, myocardial infarction, or strokecomposite
Long-term use of ticagrelor in patients with a prior myocardial infarction (>1 year) reduces ischemic events but increases the risk of major bleeding.
In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Marc P. Bonaca
Deepak L. Bhatt
Marc Cohen
New England Journal of Medicine
Harvard University
Brigham and Women's Hospital
Inserm
Building similarity graph...
Analyzing shared references across papers
Loading...
Bonaca et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69cea11e5ff5f19319758b5b — DOI: https://doi.org/10.1056/nejmoa1500857